We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aoxing Pharmaceuticals Q2 Revenue Up 27%; Net Income $2.1 Million, Up 265% Direct-To-Customer Sales Program Helps Raise Gross Margins To 79% PR Newswire FOSTER CITY, Calif., Feb. 8, 2016 FOSTER...
Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer PR Newswire FOSTER CITY, Calif., Feb. 1, 2016 FOSTER CITY, Calif., Feb. 1, 2016 /PRNewswire/ -- Aoxing Pharmaceutical Company...
Aoxing Pharma Selected to Supply Zhongtongan to the Insurance System for the City of Shanghai PR Newswire JERSEY CITY, N.J., Dec. 10, 2015 JERSEY CITY, N.J., Dec. 10, 2015 /PRNewswire/ -- Aoxing...
Aoxing Pharma Announces Opening Of Government Funded Drug Research Center PR Newswire JERSEY CITY, N.J., Dec. 4, 2015 JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing Pharmaceutical...
Aoxing Pharma Announces Resignation of CFO PR Newswire JERSEY CITY, N.J., Dec. 4, 2015 JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aoxing Pharmaceutical Company, Inc. PR Newswire NEW YORK, Dec. 3, 2015 NEW YORK, Dec. 3, 2015 /PRNewswire/...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aoxing Pharmaceutical, Inc. - AXN PR Newswire NEW YORK, Dec. 2, 2015 NEW YORK, Dec. 2, 2015 /PRNewswire/...
Aoxing Pharmaceuticals Q1 Revenue Up 92 Percent; Net Income Of $1.35 Million Direct-To-Customer Sales Program Helps Raise Gross Margin To 80 Percent PR Newswire JERSEY CITY, N.J., Nov. 13, 2015...
Drug Manufacturers - Major Stocks on the Move -- GlaxoSmithKline, Sanofi, Aerie Pharma, TherapeuticsMD, and Aoxing Pharma PR Newswire NEW YORK, July 28, 2015 NEW YORK, July 28, 2015 /PRNewswire/...
Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension From NYSEMKT LLC JERSEY CITY, NJ--(Marketwired - Jun 16, 2014) - Aoxing Pharmaceutical Company, Inc. (NYSEMKT: AXN...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Symbol | Price | Vol. |
---|---|---|
MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 1.08 (32.87%) | 1.43B |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 28.49 (5.01%) | 104.03M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 6.09 (-1.46%) | 84.6M |
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3.02 (-1.31%) | 77.93M |
XLFFinancial Select Sector | US$ 50.17 (1.27%) | 48.82M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions